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Børge G. Nordestgaard, MD, DMSC, Anne Langsted, MDL ipoprotein(a) [Lp(a)] was discovered in 1963by Kaare Berg in Norway, and elevated levelswere already then considered a cardiovascular
risk factor (1). For many years, Lp(a) received only
moderate scientiﬁc and clinical attention; however,
in recent years, important new evidence has em-
erged, and elevated Lp(a) is now considered a causal
risk factor for cardiovascular disease. Genetic vari-
ants in the LPA gene, which is responsible for encod-
ing apolipoprotein(a) [apo(a)] and determining
elevated Lp(a) levels, are associated with coronary
heart disease (2,3).
Other exciting new discoveries include evidence
that elevated Lp(a) levels likewise are a causal risk
factor for aortic valve calciﬁcation and stenosis (4,5).
In aortic valve stenosis, thickening of the aortic valve
cusps limits the outﬂow of blood from the left
ventricle of the heart, a condition that, if untreated,
can lead to heart failure and premature death. Aortic
valve stenosis affectsw2% of individuals $65 years of
age, and in those who have symptoms, 5- and 10-year
mortality approaches 50% and 90%, respectively,
without aortic valve replacement (AVR) (6). Ran-
domized trials using statins and other lipid-lowering
medications have failed to show an effect on aortic
valve stenosis, and to date, the only effective treat-
ment is AVR. Previously, risk factors for aortic valve*Editorials published in the Journal of the American College of Cardiology
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to disclose.stenosis included only bicuspid aortic valves and
rheumatic fever. Recently, however, common car-
diovascular risk factors such as smoking, high blood
pressure, high cholesterol, diabetes, male sex (6), and
now elevated Lp(a) (4,5) have emerged. As for aortic
valve stenosis, Lp(a) is also a causal risk factor for
atherosclerotic stenosis (7).
How elevated Lp(a) levels lead to aortic valve and
atherosclerotic stenosis is not completely clear, but
there are several proposed mechanisms (8,9). First, as
Lp(a) consists of a low-density lipoprotein (LDL)
cholesterol-rich particle covalently bound to an
apo(a) glycoprotein, 1 possible mechanism suggests
that Lp(a), after transfer from the bloodstream into
the wall of aortic valve cusps and the arterial intima,
leads to cholesterol deposition in a manner similar to
LDL cholesterol. This would then cause a thickening
of aortic valve cusps and the arterial intima. Second,
as apo(a) resembles plasminogen (8,9), Lp(a) may
promote thrombosis by competing with plasminogen
and thereby inhibiting the role of plasmin in dis-
solving ﬁbrin clots (10). This could then, through
ﬁbrin deposition, lead to progressive aortic valve and
atherosclerotic stenosis. Third, Lp(a) may be impor-
tant in wound healing (11): it is possible that Lp(a)
could bind to ﬁbrin and be transported to and accu-
mulate at sites of injury, thereby delivering choles-
terol via its LDL component to sites of tissue healing
and thus becoming part of the wound-healing pro-
cess. If Lp(a) accumulates at sites of wound healing,
then it can be speculated that Lp(a) might also accu-
mulate at sites of minor injury at the very beginning
of aortic valve and atherosclerotic stenosis, en-
hancing the deposition of cholesterol (11,12) and,
possibly, thrombi. Either of these may lead to further
stenosis. Indeed, Lp(a), as opposed to LDL, prefer-
entially accumulates at sites of arterial injury (13),
which seems to support the speculation that Lp(a)
may contribute to wound healing in a normal
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1248physiological way, whereas very high Lp(a) levels
could pathologically lead to aortic valve stenosis (4,5)
and atherosclerotic stenosis (7). That said, the precise
molecular mechanism by which elevated levels of
Lp(a) may promote cholesterol deposition, throm-
bosis, and/or wound healing, eventually causing
aortic valve and atherosclerotic stenosis, is not well
understood.SEE PAGE 1236In this issue of the Journal, Capoulade et al. (14)
report on 220 patients with mild-to-moderate aortic
valve stenosis who were followed for 3.5 years,
observing that both elevated levels of Lp(a) and
elevated levels of oxidized phospholipids on apoli-
poprotein B are associated with increased progression
of aortic valve stenosis. These are novel, timely, and
important ﬁndings. As oxidized phospholipids are
carried mainly by Lp(a) (15), it is speculated that Lp(a)
as an independent predictor of aortic valve stenosis
could be explained by oxidized phospholipids (14).
Wisely, as levels of Lp(a) and oxidized phospholipids
are highly correlated, and as the results for the 2
measurements are almost identical, Capoulade et al.
(14) never conclude that oxidized phospholipids are
the cause of aortic valve stenosis progression. Inter-
estingly, the relative progression rate of aortic valve
stenosis for high versus low Lp(a) levels was most
pronounced in individuals #57 years of age, sug-
gesting that because of the strong genetic deter-
mination of Lp(a), its pathological role is most
pronounced in the young (14).
Capoulade et al. (14) also speculate mechanistically
on how oxidized phospholipids can lead to aortic
valve stenosis through pro-inﬂammatory and pro-
calcifying effects, but no data are presented to sup-
port such hypotheses. Interestingly, in a study of
>100,000 individuals, we recently observed no causal
association between elevated levels of Lp(a) andwhole body low-grade inﬂammation as determined
by measurements of C-reactive protein, despite a
causal association with aortic valve stenosis and
myocardial infarction (16). Our study cannot exclude
inﬂammation locally at aortic valve cusps or in the
arterial intima. However, we believe that it is prudent
to also consider the possibility that elevated Lp(a)
could lead to aortic valve and atherosclerotic stenosis
by mechanisms independent of inﬂammation and
oxidized phospholipids on Lp(a), such as through the
kringle IV, type 2 size polymorphism in apo(a), the
main genetic determinant of Lp(a) levels. Also, it
should be considered that the measurement of
oxidized phospholipids might act as an indirect
measurement of Lp(a) levels and thus of the kringle
IV, type 2 size polymorphism.
Future research should: 1) provide a better under-
standing of how elevated Lp(a) causes aortic
valve and atherosclerotic stenosis, including the
potential role of oxidized phospholipids; 2) conﬁrm
the ﬁndings of Capoulade et al. (14) in larger and
better-powered studies; 3) address whether oxidized
phospholipids provide important evidence beyond
the mere measurement of Lp(a) levels; and ﬁnally and
of utmost importance, 4) include randomized trials
aimed at reducing Lp(a) and oxidized phospholipids
to hopefully reduce the risk of aortic valve and
atherosclerotic stenosis and, as a consequence,
reduce the risk of AVR surgery and coronary heart
disease. Such additional evidence will help us better
understand the precise molecular mechanism of how
elevated Lp(a) causes aortic valve and atherosclerotic
stenosis.
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